HRMY Q4 2022 Earnings — Harmony Biosciences Holdings, Inc. Revenue & Financial Results | Market Cap Arena

HRMYHarmony Biosciences Holdings, Inc.

$2B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$128M+40.7% YoY

Gross Profit

$101M79.0% margin

Operating Income

$48M37.1% margin

Net Income

$49M37.8% margin

EPS (Diluted)

$0.79

QoQ Revenue Growth

+9.5%

Cash Flow

Operating Cash Flow

$27M

Free Cash Flow

$27M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$674M

Total Liabilities

$271M

Stockholders' Equity

$403M

Cash & Equivalents

$244M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$128M	$91M	+40.7%
Gross Profit	$101M	$73M	+38.2%
Operating Income	$48M	$29M	+66.3%
Net Income	$49M	$23M	+113.6%